论坛里IMS的 Market Prognosis China （2009-2013 IMS 中国医药行业市场研究分析报告）的帖子大概有5个，但10年后出的好像就没有分享了。
https://bbs.pinggu.org/thread-971587-1-1.html （免费）
https://bbs.pinggu.org/thread-886405-1-1.html （3币）
https://bbs.pinggu.org/thread-550661-1-1.html （5币）
https://bbs.pinggu.org/thread-2125034-1-1.html （20币）
https://bbs.pinggu.org/thread-970673-1-1.html （30币）

发个2012年出的吧
IMS Market Prognosis 2012-2016
CHINA
发布报告的机构名称：IMS
报告发布时间：2012
报告页数：105 pages
报告的文件格式：PDF
报告大小：1.17M

报告目录
IMS MARKET PROGNOSIS ..........................................................................................6
MARKET OVERVIEW AND FORECASTS ........................................................................7
MARKET SYNOPSIS ................................................................................................................................ 7
TOTAL MARKET FORECASTS 2012-2016 ..................................................................................................... 9
ANALYSIS OF REBATES AND DISCOUNTS ........................................................................................................ 9
SUMMARY OF THE PROGNOSIS ...................................................................................................................... 9
HOSPITAL SECTOR OVERVIEW ................................................................................................................ 11
HOSPITAL SECTOR FORECASTS .................................................................................................................... 13
EVENT ANALYSIS ................................................................................................................................. 15
FORECASTING DATA AND METHODS ....................................................................................................... 20
DATA SOURCES ........................................................................................................................................ 20
BASELINE EXTRAPOLATIONS ....................................................................................................................... 20
HOSPITAL SECTOR BASELINE EXTRAPOLATIONS ............................................................................................ 21
ECONOMIC INDICATORS ............................................................................................................................. 22
THERAPEUTIC CLASS FORECASTS ........................................................................................................... 23
IMS MARKET PROGNOSIS REPORT ..........................................................................25
BUSINESS ENVIRONMENT .......................................................................................26
ECONOMIC ENVIRONMENT ..................................................................................................................... 26
ECONOMIC GROWTH ................................................................................................................................. 26
INFLATION ............................................................................................................................................... 26
POPULATION, EMPLOYMENT AND INCOME ..................................................................................................... 26
FISCAL POLICY .......................................................................................................................................... 27
MONETARY POLICY .................................................................................................................................... 27
FOREIGN TRADE AND CURRENT ACCOUNT ..................................................................................................... 27
EXCHANGE RATE ....................................................................................................................................... 28
POLITICAL ENVIRONMENT ...................................................................................................................... 30
POLITICAL INSTITUTIONS ........................................................................................................................... 30
CURRENT GOVERNMENT .............................................................................................................................. 30
18th PARTY CONGRESS 2012 ....................................................................................................................... 31
WUKAN VILLAGE PROTEST .......................................................................................................................... 32
INTERNATIONAL RELATIONS ........................................................................................................................ 32
HEALTHCARE ENVIRONMENT ...................................................................................33
HEALTHCARE PROVISION ....................................................................................................................... 33
Market Prognosis Scenario 2012-2016: Healthcare Provision ............................................................................ 33
HEALTHCARE SYSTEM ................................................................................................................................ 34
HEALTH STATUS ........................................................................................................................................ 36
HEALTHCARE FINANCING AND EXPENDITURE ................................................................................................ 38
PHARMACEUTICAL EXPENDITURE ................................................................................................................. 38
HEALTHCARE POLICY ................................................................................................................................. 41
DRUG POLICY ........................................................................................................................................... 42
HEALTH INSURANCE .................................................................................................................................. 43
HOSPITAL SECTOR .................................................................................................................................... 45
HOSPITAL DRUG PROCUREMENT .................................................................................................................. 48
COMMUNITY CARE ..................................................................................................................................... 50
PRESCRIBING AND DISPENSING ............................................................................................................. 52
Market Prognosis Scenario 2012-2016: Prescribing and Dispensing ................................................................... 52
PRESCRIBING INFLUENCES .......................................................................................................................... 52
ANTIBIOTIC PRESCRIBING .......................................................................................................................... 55
ESSENTIAL DRUG LIST ............................................................................................................................... 56
NATIONAL REIMBURSEMENT DRUG LIST ....................................................................................................... 56
PATIENT CO-PAYMENT ............................................................................................................................... 58
HOSPITAL FORMULARIES ............................................................................................................................ 58
PRESCRIPTION-ONLY POLICY ....................................................................................................................... 58
SEPARATION OF PRESCRIBING AND DISPENSING ........................................................................................... 58
PRICING ............................................................................................................................................. 59
Market Prognosis Scenario 2012-2016: Pricing ............................................................................................... 59
PRICING SYSTEM ...................................................................................................................................... 59
PRICING POLICY REFORM ............................................................................................................................ 60
PRICE MONITORING .................................................................................................................................. 62
PRICE CUTS .............................................................................................................................................. 62
PRICE TRENDS .......................................................................................................................................... 63
PHARMACOECONOMICS .............................................................................................................................. 64
DISCOUNTS AND MARGINS ......................................................................................................................... 64
REGULATORY ENVIRONMENT .................................................................................................................. 66
Market Prognosis Scenario 2012-2016: Regulatory Environment ....................................................................... 66
STATE FOOD AND DRUG ADMINISTRATION ................................................................................................... 67
PRODUCT REGISTRATION ............................................................................................................................ 67
CLINICAL TRIALS ...................................................................................................................................... 68
GOOD MANUFACTURING PRACTICE ............................................................................................................... 68
POST-MARKETING SURVEILLANCE ................................................................................................................ 69
MARKETING AND PROMOTION ..................................................................................................................... 69
COUNTERFEITS ......................................................................................................................................... 70
INTELLECTUAL PROPERTY ............................................................................................................................ 70
PHARMACEUTICAL BUSINESS ENVIRONMENT ........................................................................................... 72
Market Prognosis Scenario 2012-2016: Pharmaceutical Business Environment .................................................... 72
OPERATING ENVIRONMENT ......................................................................................................................... 73
INDUSTRY STRUCTURE ............................................................................................................................... 74
LEADING CORPORATIONS ........................................................................................................................... 76
LEADING PRODUCTS .................................................................................................................................. 77
FOREIGN INVESTMENT ............................................................................................................................... 77
RESEARCH AND DEVELOPMENT .................................................................................................................... 78
GENERICS MARKET .................................................................................................................................... 79
DISTRIBUTION .......................................................................................................................................... 80
RETAIL PHARMACY .................................................................................................................................... 81
OTC MARKET ............................................................................................................................................ 82
SALES AND MARKETING .............................................................................................................................. 83
以下略。。。。